Area of research
Pathology and Forensic Medicine · Oncology
Research interest
Research interests include Lymphoma Diagnosis and Treatment, CAR-T cell therapy research, Chronic Lymphocytic Leukemia Research, and CNS Lymphoma Diagnosis and Treatment.
Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma
SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas – Aiming to improve therapy, outcomes, and validate a prospective frailty tool
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma
Randomized Phase III Study of Alisertib or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study
The Genetic Basis of Hepatosplenic T-cell Lymphoma
PHASE I/II STUDY OF CHOEP PLUS LENALIDOMIDE AS INITIAL THERAPY FOR PATIENTS WITH STAGE II‐IV PERIPHERAL T‐CELL NON‐HODGKIN LYMPHOMA: PHASE I RESULTS FROM THE T‐CELL CONSORTIUM
Safety and Preliminary Efficacy Results of a Phase I First-in-Human Study of the Novel Notch-1 Targeting Antibody Brontictuzumab (OMP-52M51) Administered Intravenously to Patients with Hematologic Malignancies
A phase <scp>II</scp> study of cyclophosphamide, etoposide, vincristine and prednisone ( <scp>CEOP</scp> ) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T‐cell lymphoma ( <scp>PTCL</scp> ): final results from the T‐ cell consortium trial
Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma